Experiment Number: 99020-02 P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Type: 14-DAY

Test Compound: Pulegone

C99020

Test Compound: Pulegone CAS Number: 89-82-7

Date Report Requested: 10/22/2014 Time Report Requested: 12:22:30

First Dose M/F: NA / NA

Lab: BAT

Route: GAVAGE

C Number:

Species/Strain: Mouse/B6C3F1

Lock Date: 10/24/2001

Cage Range: All

Date Range: All

Reasons For Removal:

Removal Date Range: All

Treatment Groups: All

Study Gender: Both

PWG Approval Date NONE

Species/Strain: Mouse/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

**Test Type:** 14-DAY **Route:** GAVAGE

None

None

HEMATOPOIETIC SYSTEM

Test Compound: Pulegone CAS Number: 89-82-7

Date Report Requested: 10/22/2014 Time Report Requested: 12:22:30

First Dose M/F: NA / NA

B6C3F1 Mouse MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
Disposition Summary						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Natural Death						1
Survivors						
Terminal Sacrifice	5	5	5	5	5	4
Animals Examined Microscopically	5				5	5
ALIMENTARY SYSTEM						
Liver	(5)	(0)	(0)	(0)	(5)	(5)
Bile Duct, Hyperplasia						3 (60%)
Fatty Change, Diffuse						1 (20%)
Hepatocyte, Degeneration						2 (40%)
Infiltration Cellular, Mononuclear Cl	3 (60%)				2 (40%)	2 (40%)
Inflammation					1 (20%)	3 (60%)
Necrosis	1 (20%)					5 (100%)
Vacuolization Cytoplasmic						1 (20%)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
N.1						

a - Number of animals examined microscopically at site and number of animals with lesion

Species/Strain: Mouse/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

**Test Type:** 14-DAY **Route:** GAVAGE

Test Compound: Pulegone CAS Number: 89-82-7

Date Report Requested: 10/22/2014 Time Report Requested: 12:22:30

First Dose M/F: NA / NA

B6C3F1 Mouse MALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
INTEGUMENTARY SYSTEM None						
MUSCULOSKELETAL SYSTEM None						
NERVOUS SYSTEM Brain	(5)	(0)	(0)	(0)	(0)	(5)
RESPIRATORY SYSTEM Lung	(5)	(0)	(0)	(0)	(0)	(5)
SPECIAL SENSES SYSTEM None						
URINARY SYSTEM						
Kidney	(5)	(0)	(0)	(0)	(5)	(5)
Infiltration Cellular, Mononuclear Cl	2 (40%)					
Nephropathy	1 (20%)					2 (40%)

<sup>\*\*\*</sup>END OF MALE DATA\*\*\*

Species/Strain: Mouse/B6C3F1

HEMATOPOIETIC SYSTEM

None

Test Type: 14-DAY

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

Test Compound: Pulegone CAS Number: 89-82-7

Date Report Requested: 10/22/2014
Time Report Requested: 12:22:30

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
Disposition Summary						
Animals Initially In Study Early Deaths	5	5	5	5	5	5
Moribund Sacrifice Natural Death						2 2
Survivors						
Terminal Sacrifice Animals Examined Microscopically	5 5	5	5	5	5 5	1 5
ALIMENTARY SYSTEM						
Liver	(5)	(0)	(0)	(0)	(5)	(5)
Bile Duct, Hyperplasia						1 (20%)
Fatty Change, Diffuse						4 (80%)
Infiltration Cellular, Mononuclear CI	5 (100%)				2 (40%)	
Inflammation						3 (60%)
Mineralization						3 (60%)
Necrosis	1 (20%)					4 (80%)
Vacuolization Cytoplasmic						4 (80%)
CARDIOVASCULAR SYSTEM None						
ENDOCRINE SYSTEM None						
GENERAL BODY SYSTEM None						
GENITAL SYSTEM None						

a - Number of animals examined microscopically at site and number of animals with lesion

Species/Strain: Mouse/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)

**Test Type:** 14-DAY **Route:** GAVAGE

Test Compound: Pulegone CAS Number: 89-82-7

Date Report Requested: 10/22/2014 Time Report Requested: 12:22:30

First Dose M/F: NA / NA

B6C3F1 Mouse FEMALE	0 MG/KG	18.75 MG/KG	37.5 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
INTEGUMENTARY SYSTEM None						
MUSCULOSKELETAL SYSTEM None						
NERVOUS SYSTEM Brain	(5)	(0)	(0)	(0)	(0)	(5)
RESPIRATORY SYSTEM Lung	(5)	(0)	(0)	(0)	(0)	(5)
SPECIAL SENSES SYSTEM None						
URINARY SYSTEM Kidney Nephropathy	(5)	(0)	(0)	(0)	(5) 1 (20%)	(5)

<sup>\*\*</sup> END OF REPORT \*\*